US demand for biochip products and services will grow nearly ten percent annually through 2012. Growth will be led by uses in drug discovery and epidemiological research, with protein characterization and analysis providing the fastest expanding technologies. Contract research and outsourcing will post the strongest gains among biochip services.
This study analyzes the $1.6 billion US biochips industry. It presents historical demand data for the years 1997, 2002 and 2007, and forecasts for 2012 and 2017 by technology (gene expression, SNP identification and genotyping, proteomic), product (e.g., microarrays, biochip reagents and consumables, biochip instruments, biochip software), service, application (e.g., drug discovery, life science research, in vitro diagnostic testing, disease management, forensic medicine, drugs-of-abuse testing) and market (e.g., pharmaceutical companies, biotechnology companies, colleges and universities, medical providers).
The study also considers market environment factors, details industry structure, evaluates company market share and profiles 26 industry players, including Illumina, Affymetrix and Applied Biosystems.
